Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

StrataNGS™ Test

Laboratory Developed Test
Related tests:


The StrataNGS Test is a clinical assay performed in a CLIA-certified laboratory. It is a solid tumor, pan-cancer Next Generation Sequencing (NGS) test to detect mutations across 87 genes, copy number variations (amplifications and deep deletions) across 31 genes, and fusion events across 46 driver genes. The assay utilizes the Ion S5 sequencing workflow, with libraries created using the StrataNGS Assay, incorporating Ampliseq chemistry. The assay runs up to 24 patient samples on one Ion 540 chip, utilizing both DNA and RNA from each sample.
Solid Tumor
ALK (Anaplastic lymphoma kinase), ATM (ATM serine/threonine kinase), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), EGFR (Epidermal growth factor receptor)
See More ...
Next-Generation Sequencing (NGS)